Inicio
Este sitio está destinado a profesionales de la salud.

Módulo 1 del Navegador sobre la fibrosis pulmonar: Contexto y la «ventana de oportunidad» perdida

Compartir

Descripción

Esta actividad cuenta con el apoyo de una subvención educativa independiente de BMS. Este programa educativo en línea se ha diseñado para profesionales sanitarios de todo el mundo, excepto del Reino Unido.

Únete a los expertos Fernando Martínez, doctor en Medicina, y Corey Kershaw, doctor en Medicina, para un análisis basado en casos sobre la identificación precoz del riesgo en la enfermedad pulmonar intersticial asociada a la artritis reumatoide (EPI-AR). En esta sesión se analiza cómo los síntomas respiratorios sutiles suelen pasarse por alto, y se demuestra cómo la elaboración de perfiles de riesgo estructurados puede evitar retrasos en el diagnóstico antes de que se produzca una pérdida manifiesta e irreversible de la función pulmonar.

Este es el primer módulo de un total de cuatro. Los módulos dos, tres y cuatro se pueden consultar aquí.

Aspectos destacados de la sesión

  • Reconocer que los síntomas inespecíficos, como la tos seca y la disnea sutil, constituyen señales de alto riesgo en pacientes con AR que requieren una investigación inmediata.
  • Aplicar las directrices de la ACR/CHEST de 2023 para realizar un cribado condicional de pacientes asintomáticos en riesgo mediante herramientas estructuradas de evaluación de riesgos.
  • Evaluar los factores de riesgo del paciente —incluidos los niveles elevados de anticuerpos anti-CCP en la serología, los antecedentes de tabaquismo y la duración de la AR— para derivar oportunamente a los pacientes a pruebas de función pulmonar (PFP) y a una tomografía computarizada de alta resolución (TCAR).
  • Implementar vías de colaboración interespecialística entre reumatología y neumología para establecer puntos de control conjuntos para la detección precoz.

Público destinatario

Esta actividad está dirigida a neumólogos, reumatólogos, radiólogos torácicos, patólogos, enfermeros especializados en neumología y auxiliares médicos que desempeñan un papel fundamental en el diagnóstico y el tratamiento de la FPI y la FPP. También está diseñada para médicos de cabecera, terapeutas respiratorios, farmacéuticos y otros profesionales sanitarios multidisciplinares que participan en la atención de pacientes con fibrosis pulmonar.

Profesorado

El Dr. Fernando Martínez es catedrático de la División de Medicina Pulmonar y director interino del Departamento de Medicina de la Facultad de Medicina Chan de la Universidad de Massachusetts, en Worcester (Massachusetts). Titulado en Medicina y con un máster en Ciencias, es un destacado clínico e investigador con una larga trayectoria dedicada a la medicina académica, la atención al paciente y las estrategias multidisciplinares en medicina respiratoria.

El Dr. Corey Kershaw es profesor del Departamento de Medicina Interna, dentro de la División de Medicina Pulmonar y de Cuidados Intensivos de la UT Southwestern. Desempeña el cargo de jefe de servicios clínicos de la División de Medicina Pulmonar y de Cuidados Intensivos, así como el de director médico de la Unidad de Cuidados Intensivos Médicos y de Terapia Respiratoria del Hospital Universitario William P. Clements Jr. Cuenta con una amplia experiencia clínica en el tratamiento de afecciones pulmonares complejas y en medicina de cuidados intensivos.

Declaraciones de intereses

De conformidad con las directrices de EBAC®, todos los ponentes y moderadores que participan en este programa han declarado o señalado cualquier posible conflicto de intereses que pudiera sesgar sus presentaciones. El Comité Organizador o el director del curso es responsable de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a la audiencia antes del inicio de las actividades de formación continua.

El Dr. Fernando Martínez, ponente de esta actividad, ha revelado relaciones financieras en los últimos 36 meses con las siguientes empresas no elegibles: asesor de Lung Therapeutics; consultor, asesor y ponente de Boehringer Ingelheim y Chiesi; miembro del Comité de Supervisión de Datos y Seguridad (DSMB) de Pliant; investigador de AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro y Vicore.

El Dr. Corey Kershaw, ponente de esta actividad, ha declarado haber mantenido relaciones financieras en los últimos 36 meses con las siguientes empresas no elegibles: consultor, asesor y ponente para Boehringer Ingelheim; investigador para Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics y United Therapeutics.

El personal de MedAll, así como los planificadores y revisores, no tienen relaciones financieras relevantes con empresas no elegibles que deban declararse.

Información sobre la formación médica continua (FMC) de EBAC®:

Esta actividad se ha planificado y llevado a cabo de conformidad con los requisitos y políticas de acreditación de la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC).

MedAll es un proveedor acreditado por la EBAC desde 2025. La Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC) acredita programas de formación continua (FC) para la comunidad médica internacional.

Este programa está acreditado por la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC®) con 15 minutos de tiempo efectivo de formación.

De conformidad con las directrices de la EBAC, todos los ponentes y moderadores que participan en este programa han revelado o señalado posibles conflictos de intereses que podrían dar lugar a un sesgo en las presentaciones. El Comité Organizador y el director del curso son responsables de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a los asistentes antes del inicio de las actividades de formación continua.

La EBAC® mantiene un acuerdo de reconocimiento mutuo de equivalencia sustantiva con el Consejo de Acreditación de Estados Unidos para la Formación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá, respectivamente.

Mediante un acuerdo entre la Junta Europea de Acreditación de la Formación Continua para Profesionales de la Salud (EBAC®) y la Asociación Médica Americana (AMA), los médicos pueden convertir los créditos de formación médica continua externa de la EBAC® en créditos AMA PRA de categoría 1. La información sobre el proceso para convertir créditos EBAC® en créditos AMA se puede consultar en la página web de la AMA. Otros profesionales sanitarios pueden obtener de la AMA un certificado de participación en una actividad que da derecho a la conversión de créditos en créditos AMA PRA de categoría 1.

El Consejo de Acreditación para la Educación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá mantienen un acuerdo de equivalencia sustantiva de los sistemas de acreditación con EBAC.

EBAC® es miembro de la Academia Internacional para la Acreditación del Desarrollo Profesional Continuo (IACPDA) y miembro asociado de la Asociación Internacional de Autoridades Reguladoras Médicas (IAMRA).

Cómo obtener su crédito de formación médica continua (FMC) de EBAC®:

Para obtener su crédito de FMC y recibir su certificado, participe en la actividad y complete la evaluación al final. Recibirá un enlace a su certificado tras completar la evaluación.

Costes de participación

La participación en este programa es gratuita.

Esta actividad de formación continua estará activa a partir del 1 de noviembre de 2026 y caducará el 30 de septiembre de 2027.

Tiempo estimado para completar esta actividad: 15 minutos

Objetivos de aprendizaje

Al finalizar esta actividad, los participantes serán capaces de:

  • Incorporar la estratificación del riesgo, las técnicas de imagen de alta resolución y la evaluación multidisciplinar para diferenciar y diagnosticar la FPI y la FPP de otras enfermedades pulmonares intersticiales de forma precoz y precisa.
  • Poner en práctica estrategias multidisciplinares de diagnóstico y tratamiento para mejorar la detección oportuna, la derivación y la atención coordinada de los pacientes con FPI.
  • Aplicar los conocimientos sobre los mecanismos de acción y la evidencia clínica a las decisiones terapéuticas, incluyendo la selección de pacientes y el momento adecuado para iniciar el tratamiento.

Comunidades similares

Ver todo

Eventos y vídeos bajo demanda similares

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hello and welcome to this Medal training program. If this is your first time participating in a Medal program, we'd extend a very special welcome to you. Uh, Corey is at UT Southwestern, uh, in Texas. Uh, Toby is at the University of Southern California, uh, and I'm at the University of Massachusetts. All right, so let me introduce you to Margaret. So she has been in 3 different clinic rooms over the 6 months before anybody even ordered a pulmonary function test. We're gonna try to sort of figure out why that's happened, uh, what could have been done differently at each of those moments and, and how that's gonna impact, uh, her, uh, her care. OK. So here's Margaret. For a long time I put it down to age. I have arthritis, so if the stairs were harder than they used to be, I assumed that was why. What made me take it seriously was the cough, a dry cough that went on for months. I mentioned the breathlessness at several appointments. Each time it was put down to something else. Now, this is one of those polls that I warned you about. So remember that there are a couple of approaches to being able to answer these polls. Uh, and this this question is, how confident are you that you would recognize and act on early ILD in a patient like Margaret? You only got 5 options, so it's easy from not at all confident to completely confident. You're gonna see this question again at the end of the hour. So we wanna see any changes that occur over time. So go ahead and answer away. Hello, I'm Doctor Corey Kershaw. I am a professor of medicine in the division of Pulmonary and Critical Care Medicine at the University of Texas Southwestern Medical Center in Dallas, Texas, and I'm very pleased to join you today. Uh, I'm gonna be talking about a visit that our patient had in her rheumatology clinic. And we're gonna call this the missed window because um I believe you all see that there are some opportunities that go by where we could have intervened, um, at least diagnostically early for our patients. So we'll start here. This is Margaret. We've met her. She's 66 and she's here for a routine rheumatology clinic appointment. Her history is relevant for serropositive rheumatoid arthritis that was diagnosed when she was 61. That's 5 years ago. She's currently managed with methotrexate 20 mg once per week plus folic acid, and this regimen is working quite well for her. Her joints are well-controlled. She used to smoke, 20 pack years, quit at age 55. Um, she worked as a school teacher. She's now retired. She walks daily for exercise, but she admits to us that she is slowing down a bit. Today's visit, when we're discussing things, um, she reports a dry cough, um, for the last 4 months, and she thinks it's related to her allergies, so probably nothing to worry about. Um, on her daily walks, because it is a routine for her, she knows what her, um, capacity is. She's noticed that she's beginning to be a bit more breathless on a hill that was manageable previously and You know, she doesn't think anything of it. She thinks it's just deconditioning. She's getting a bit older. Um, she has no respiratory complaints on her own until you ask. Um, so these things did not come up at all until we ask these questions. And on a, um, On our examination, she has crackles in both lung bases when we listen to her chest. So, you know, our agenda coming into this appointment, you know, we're as a rheumatologist in this setting, you know, I'm gonna ask about her joint scores. Uh, she takes methotrexate, so we have to do some routine blood tests to, um, Uh, ensure she's not having any toxicity. I asked her about flu vaccinations, important for all of our patients. Um, but there's nothing on the agenda that says anything about her lungs, and I think we'll find that that is very relevant as we go through, um, Margaret's symptoms here. So Let's start, let's go detail by detail here. So the first thing, um, that's relevant for Margaret is she's had rheumatoid arthritis for 5 years and our context here is, um, looking at the possibility that Margaret may have an interstitial lung disease in the setting of her rheumatoid arthritis. And in fact, um, rheumatoid arthritis is a significant risk for ILD. There's a 7.7% lifetime ILD risk in patients with rheumatoid arthritis compared to patients who don't have arthritis. Um, And the reason that's important for us to remember is that a patient comes to us with rheumatoid arthritis and has pulmonary complaints, a dry cough, crackles on exam, we should not default to what in a patient without RA may indeed be true that this is maybe allergy-related. Maybe it's related to her getting older. We have to exclude ILD 7.7% lifetime risk. That's quite significant. So we really need to be attuned. To that possibility and having a, you know, just having it through uh RA throughout your life increases the risk for ILD ninefold. 1 in 13 patients will develop RA will develop ILD when they have RA, um. And We shrugged off Margaret's symptoms. She certainly didn't seem concerned about them. That land right on that baseline that we should be concerned about. Um, and we should not rule out ILD as a consideration just because she's had RA for some time now. And in fact, the medium time that a patient has been diagnosed with rheumatoid arthritis before they develop ILD is 5 years. Um, real-world average 3.3 years, um, from the time the patient's diagnosed with, uh, rheumatoid arthritis until they are diagnosed with ILD and that incidence climbs throughout the first decade of diagnosis. So, you see a patient, you're diagnosing with rheumatoid arthritis, really that first decade, it has to be part of our every clinic assessment. Uh, for pulmonary symptoms because the risk is significant that the patient may develop an ILD during that time. So we need to be very attuned to that possibility. Um, Margaret's labs, let's consider that. So Margaret is, um, CCP positive. And in fact, being CCC positive itself is a notable risk for developing ILD and in fact, a high titer is especially concerning, 3 times. The upper limit of normal is considered um a high positive serology and the higher the tighter, the stronger the ILD association. So you can see the hazard ratio for developing ILD is 9 in patients that are seronegative, um, in patients that don't have RA and even patients that are, that have RA that don't, that aren't CC positive, they still have a risk, but it's significantly higher if they are CC CCC positive, CCP positive, excuse me. Um, and so certainly in a patient we're seeing in our rheumatology clinic that is CCP positive with the rheumatoid arthritis, very significant risk for developing ILD later on. Margaret has a smoking history. Great that she quit, but that risk, um, her smoking history increases her risk of developing RAILD and that risk does not go away just because she quit. Um, so even ex-smokers still have a risk. Great that she quit smoking, great for other aspects of her health, but it doesn't, um, make the risk for ILD go away. So, the the odds ratio for for RAILD in ever smokers is 2.8. So, The, the things that really go along with her risk is that um in terms of this aspect of her history is she's an ex-smoker and she's seropositive. If you, if you're also a man, the odds ratio goes up to 6.9. Margaret is female, so she doesn't have that stacked risk, but still being an um ever smoker, her odds ratio of developing ILD. 2.8. Um, as part of her visit, um, she gets, uh, a Rodden skin score because it's important according to the, um, SARD ILD guidelines that we exclude patients on the scleroderma spectrum first. She has no skin thickening, which is reassuring because having skin thickening itself would be a risk factor for ILD, but that does not exclude her from the risk because she has other features in her diagnosis that place her at risk of developing ILD. What about her methotrexate? It, it is a Common, I'm gonna use the term misconception that a patient on methotrexate is at risk for developing a fibrosing ILD, um, and in fact, that's not actually true, especially in the setting of somebody with rheumatoid arthritis, um, being on methotrexate lowers the risk of, um, Rheumatoid arthritis and actually prolongs the onset of it developing later from the RA. So, it's so important that when you see a patient in your clinic that you're managing with methotrexate, especially if it's working well, you know, methotrexate is a wonderful drug for the arthralgias that go with rheumatoid arthritis. Um, you hear crackles on exam, you do some other workup and it looks like the patient has an early ILD. Don't stop the methotrexate. In fact, keep it on because that's, you know, you know, perhaps gonna help them, and you should assume that perhaps the ILD is actually from the RA itself and not from the drug. So this is not a risk factor. It actually lowers her risk of developing ILD being on methotrexate. So, let's talk about just some of the other um risks that, you know, we need to consider here and why this is important. So,